Business Context and Reporting Period
This Form 6-K filing by NovaBridge Biosciences covers the month of September 2026. The report details the voting results of the Company's 2026 Annual General Meeting (AGM) held on September 8, 2026, in Shanghai, China.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes rather than financial performance.
Material Changes
The primary material change reported is the removal of Ms. Xin Liu from her position as a director of the Company, effective immediately upon the passing of the resolution at the AGM.
Shareholder Voting Results
The AGM was attended by holders of 121,294,288 shares (approximately 44.8% of the 270,740,383 shares outstanding as of the July 27, 2026 record date), constituting a quorum. The voting results for the removal of Ms. Xin Liu were as follows:
- For: 107,925,508 votes
- Against: 13,313,327 votes
- Abstain: 55,453 votes
Outlook, Risks, and Contingencies
The filing text does not provide a clear value for future guidance, management commentary on business outlook, specific risks, or contingencies beyond the immediate change in board composition.
Key Facts for Investor Verification
- Ms. Xin Liu has been removed from the Board of Directors effective September 8, 2026.
- Shareholder attendance represented 44.8% of total outstanding shares.
- The resolution to remove the director passed with approximately 89% of votes cast in favor.
- No financial performance data is included in this specific filing.